--Savara Submitted the MOLBREEVI Biologics License Application (BLA) in December 2025 for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) ...
-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested --
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...
-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496...
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will...
-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- ...
NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options
LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of...